WithdrawnNot Applicable

Biomarker for Maroteaux-Lamy Disease (BioMaroteaux)

Stopped: Transition into BioMetabol

Egypt, Germany, India0Started 2018-08-20

Plain-language summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Maroteaux-Lamy disease from blood

Who can participate

Age range12 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Informed consent will be obtained from the patient or the parents before any study related procedures. * Patients older than 12 months * The patient has a diagnosis of Maroteaux-Lamy disease Exclusion Criteria: * No Informed consent from the patient or the parents before any study related procedures * Patients younger than 12 months * The patient has no diagnosis of Maroteaux-Lamy disease

What they're measuring

Development of a new MS-based biomarker for the early and sensitive diagnosis of Maroteaux-Lamy disease from blood (plasma)

Timeframe: 24 month

Trial details

NCT IDNCT01458613

SponsorCENTOGENE GmbH Rostock

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-02-28

View on ClinicalTrials.gov More Lysosomal Storage Disease trials